[
  {
    "ts": null,
    "headline": "IQVIA Holdings Inc. stock outperforms competitors on strong trading day",
    "summary": "IQVIA Holdings Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=9d745d8d6b924ff6b8422be76f0c3539c08fa6da7bde2c638836081468402879",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748365440,
      "headline": "IQVIA Holdings Inc. stock outperforms competitors on strong trading day",
      "id": 134731850,
      "image": "",
      "related": "IQV",
      "source": "MarketWatch",
      "summary": "IQVIA Holdings Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=9d745d8d6b924ff6b8422be76f0c3539c08fa6da7bde2c638836081468402879"
    }
  },
  {
    "ts": null,
    "headline": "Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF",
    "summary": "Rein Therapeutics (\"Rein\") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced today that the first patient has been dosed in the RENEW Phase 2 trial of its lead asset, LTI-03, a novel, multi-pathway, Caveolin-1-related peptide for the treatment of IPF.",
    "url": "https://finnhub.io/api/news?id=a0c49d7a79edc62f86d35a7f1f8b14a0f706dc8022f354c59714a604d6a7af6e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748343600,
      "headline": "Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF",
      "id": 134717253,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "IQV",
      "source": "Yahoo",
      "summary": "Rein Therapeutics (\"Rein\") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, announced today that the first patient has been dosed in the RENEW Phase 2 trial of its lead asset, LTI-03, a novel, multi-pathway, Caveolin-1-related peptide for the treatment of IPF.",
      "url": "https://finnhub.io/api/news?id=a0c49d7a79edc62f86d35a7f1f8b14a0f706dc8022f354c59714a604d6a7af6e"
    }
  },
  {
    "ts": null,
    "headline": "IQVIA Holdings Inc. Announces First Patient Dosed in Renew Phase 2 Trial of Lti-03 in Patients with Ipf",
    "summary": "IQVIA Holdings Inc. announced that the first patient has been dosed in the RENEW Phase 2 trial of its lead asset, LTI-03, a novel, multi-pathway, Caveolin-1-related peptide for the treatment of IPF....",
    "url": "https://finnhub.io/api/news?id=03dfe6cb84326a25deb5647d213cfef200fbc9fd9b70a4bd0cfbfb71bea5bdfb",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748332231,
      "headline": "IQVIA Holdings Inc. Announces First Patient Dosed in Renew Phase 2 Trial of Lti-03 in Patients with Ipf",
      "id": 134707773,
      "image": "",
      "related": "IQV",
      "source": "Finnhub",
      "summary": "IQVIA Holdings Inc. announced that the first patient has been dosed in the RENEW Phase 2 trial of its lead asset, LTI-03, a novel, multi-pathway, Caveolin-1-related peptide for the treatment of IPF....",
      "url": "https://finnhub.io/api/news?id=03dfe6cb84326a25deb5647d213cfef200fbc9fd9b70a4bd0cfbfb71bea5bdfb"
    }
  }
]